{"schema_version":"secwatch.filing_event.v1","accession":"0001555280-24-000330","form_type":"8-K","ticker":"ZTS","cik":"0001555280","company_name":"Zoetis Inc.","filed_at":"2024-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.772549+00:00","generated_at":"2026-05-30T06:01:45.607632+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Zoetis Q3 revenue $2.4B (+11%); adjusted EPS $1.58; FY guidance raised","bullets":["Revenue $2.4B, +11% reported (+14% operational); GAAP EPS $1.50 (+16% YoY).","Adjusted net income $716M, adjusted EPS $1.58 (+16% reported, +17% operational).","U.S. segment revenue $1.3B (+15%) led by mAbs (Librela, Solensia) and Simparica Trio.","International segment revenue $1.0B (+7% reported, +13% operational) with broad product strength.","FY2024 guidance raised: revenue $9.20-9.30B, adjusted EPS $5.86-5.92, operational growth 10-11%."],"urls":{"canonical":"https://secwatch.observer/filing/0001555280-24-000330","json":"https://secwatch.observer/filing/0001555280-24-000330.json","markdown":"https://secwatch.observer/filing/0001555280-24-000330.md","text":"https://secwatch.observer/filing/0001555280-24-000330.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1555280/000155528024000330/0001555280-24-000330-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1555280/000155528024000330/zts-20241104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T06:01:45.607632+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}